|
1）Chantarangkul V, Biguzzi E, Asti D, et al. Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anti-coagulant. Thromb Haemost. 2013; 110(1): 46-52
|
|
|
|
2）Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of beta 2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood. 2012; 120(16): 3360-70
|
|
|
|
|
3）de Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005; 105(4): 1540-5
|
|
|
|
|
|
4）de Laat B, van Berkel M, Urbanus RT, et al. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011; 63(12): 3960-8
|
|
|
|
|
|
5）Andreoli L, Nalli C, Motta M, et al. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocentʼ profile? Ann Rheum Dis. 2011; 70(2): 380-3
|
|
|
|
|
|
6）Sakai Y, Atsumi T, Ieko M, et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheuma. 2009; 60(8): 2457-67. PubMed PMID: 19644870
|
|
|
|
|
|
7）Akhter E, Shums Z, Norman GL, et al. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol. 2013; 40(3): 282-6. PubMed PMID: 23378459
|
|
|
|
|
|
8）Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118(17): 4714-8
|
|
|
|
|
|
9）Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012; 119(11): 2624-32
|
|
|
|
|
|
10）Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012; 64(2): 504-12
|
|
|
|
|
|
11）Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013; 52(8): 1397-403
|
|
|
|
|
|
12）Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116(8): 1336-43
|
|
|
|
|
|
13）Van OSG, Meijers JC, Agar C, et al. Induction of anti-beta2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost. 2011; 9(12): 2447-56
|
|
|
|
|
|
14）Ioannou Y, Zhang JY, Qi M, et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta 2-glycoprotein I. Arthritis Rheum. 2011; 63(9): 2774-82
|
|
|
|
|
|
15）Passam FH, Rahgozar S, Qi M, et al. Redox control of beta 2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost. 2010; 8(8): 1754-62
|
|
|
|
|
|
16）Passam FH, Rahgozar S, Qi M, et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood. 2010; 116(11): 1995-7
|
|
|
|
|
|
17）Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA. 2009; 302(11): 1210-7
|
|
|
|
|
|
18）Greco TP, Conti-Kelly AM, Anthony JR, et al. Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol. 2010; 133(5): 737-43
|
|
|
|
|
|
19）Kato M, Atsumi T, Oku K, et al. The involvement of CD36 in monocyte activation by antiphospholipid antibodies. Lupus. 2013; 22(8): 761-71
|
|
|
|
|
|
20）Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011; 70(4): 675-82
|
|
|
|
|
|
21）Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta 2 glycoprotein I antibodies. Int Immunol. 2004; 16(11): 1633-41
|
|
|
|
|
|
22）Oku K, Amengual O, Zigon P, et al. Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford). 2013; 52(10): 1775-84
|
|
|
|
|
|
23）Bohgaki M, Matsumoto M, Atsumi T, et al. Plasma gelsolin facilitates interaction between beta 2 glycoprotein I and alpha 5 beta1 integrin. J Cell Mol Med. 2011; 15(1): 141-51
|
|
|
|
|
|
24）Pennings MT, van Lummel M, Derksen RH, et al. Interaction of beta 2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost. 2006; 4(8): 1680-90
|
|
|
|
|
|
25）Allen KL, Fonseca FV, Betapudi V, et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta 2 glycoprotein I antibodies. Blood. 2012; 119(3): 884-93
|
|
|
|
|
|
26）Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10(11): 1222-6
|
|
|
|
|
|
27）Cohen D, Buurma A, Goemaere NN, et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. 2011; 225(4): 502-11
|
|
|
|
|
|
28）Oku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009; 68(6): 1030-5
|
|
|
|
|
|
29）Belmont HM, Hopkins P, Edelson HS, et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 1986; 29(9): 1085-9
|
|
|
|
|
|
30）Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am Transplant. 2013; 13(8): 2179-85
|
|
|
|
|
|
31）Lonze BE, Singer AL, Montgomery RA. Eculizu-mab and renal transplantation in a patient with CAPS. N Engl J Med. 2010; 362(18): 1744-5
|
|
|
|
|